NAT1 Antibody, HRP conjugated
-
中文名稱:NAT1兔多克隆抗體, HRP偶聯(lián)
-
貨號:CSB-PA015464LB01HU
-
規(guī)格:¥880
-
其他:
產(chǎn)品詳情
-
產(chǎn)品名稱:Rabbit anti-Homo sapiens (Human) NAT1 Polyclonal antibody
-
Uniprot No.:
-
基因名:NAT1
-
別名:AAC1 antibody; ARY1_HUMAN antibody; Arylamide acetylase 1 antibody; Arylamine N acetyltransferase 1 antibody; Arylamine N-acetyltransferase 1 antibody; mNAT antibody; Monomorphic arylamine N acetyltransferase antibody; Monomorphic arylamine N-acetyltransferase antibody; N acetyltransferase type 1 antibody; N-acetyltransferase type 1 antibody; NAT 1 antibody; NAT-1 antibody; nat1 antibody; NATI antibody
-
宿主:Rabbit
-
反應(yīng)種屬:Human
-
免疫原:Recombinant Human Arylamine N-acetyltransferase 1 protein (1-288AA)
-
免疫原種屬:Homo sapiens (Human)
-
標記方式:HRP
-
克隆類型:Polyclonal
-
抗體亞型:IgG
-
純化方式:>95%, Protein G purified
-
濃度:It differs from different batches. Please contact us to confirm it.
-
保存緩沖液:Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 -
產(chǎn)品提供形式:Liquid
-
應(yīng)用范圍:ELISA
-
Protocols:
-
儲存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
相關(guān)產(chǎn)品
靶點詳情
-
功能:Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
-
基因功能參考文獻:
- Data showed that NAT1, NAT2, and ESR1 expression were increased in primary breast tumor tissue and that NAT1 expression was much higher than NAT2. NAT1 and ESR1 expression were strongly associated, whereas NAT2 and ESR1 expression were not. Although NAT1 and NAT2 expression were associated, the magnitude was moderate. PMID: 29901116
- the results suggested that there was no association between NAT1*10 allele and bladder cancer risk (meta-analysis). PMID: 28604993
- identified a novel endogenous role for human NAT1 that might explain some of its effects in cancer cell growth and survival PMID: 27865712
- N-acetyltransferase polymorphisms are associated with risk of lymphoma subtypes. PMID: 25689677
- The association of colorectal adenomas with the rs6983267 variant at 8q24 was considered as 'highly credible', the 'less credible' associations were identified with a further four variants of four independent genes: MTHFR c.677C>T p.A222V(rs1801133), TP53 c.215C>G p.R72P (rs1042522), NQO1 c.559C>T p.P187S (rs1800566), and NAT1 alleles imputed as fast acetylator genotypes. [meta-analysis] PMID: 26451011
- The rs1799931(G>A) genotype was detected in the control population but not in the T2DM population. The wild type (G) allele frequency was higher in T2DM than controls. The mutant allele (A) in rs1799931(G>A) had a protective effect for T2DM. PMID: 26409796
- NAT1 genotype affects thioguanine nucleotide levels in patients treated with thiopurines and aminosalicylates and could therefore influence the toxicity and efficacy of these drugs. PMID: 25834322
- NAT1 genetic polymorphisms were found to be a risk factor for smokers in the Black population of South Africa with esophageal squamous cell carcinoma. PMID: 25886288
- NAT1 has a role in the metabolic pathway of nicotine/cotinine and/or their metabolites. PMID: 25156213
- We report that miR-1290 directly targets the NAT1 3'-UTR and that NAT1 protein expression is correlated with improved OS of breast cancer patients. PMID: 25528056
- Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine PMID: 25413361
- Candidate gene NAT1 were elevated in male breast cancer biopsies compared to those from female patients without regard to Estrogen Receptors status. PMID: 24656773
- Data suggest that NAT1/NAT2 participate in biotransformation of many aromatic/heterocyclic amines; molecular models have been developed regarding acetylation mechanism, active site structure, and substrate/inhibitor-binding specificity. [REVIEW] PMID: 23517104
- Epidemiological studies suggest that the NAT1 and NAT2 acetylation polymorphisms modify the risk of developing cancers of the urinary bladder, colorectal, breast, head and neck, and lung PMID: 23420430
- the present study provides evidence for the role of NAT1 and NAT2 variations in NSCLP, and indicates that interactions between the NAT1 and NAT2 genes may be important in susceptibility to NSCLP. PMID: 23660777
- NAT1 rapid acetylation alone as well as combination of NAT1 rapid-NAT2 slow acetylation did not modulate the risk of oral precancer and cancer in an Indian patient population. PMID: 23168701
- Only ADP and ATP are suitable substrates for human AAC1. PMID: 23173940
- Complementation studies revealed that the N-terminal domain of L9 is necessary and sufficient to improve the fitness of some Der mutants, suggesting that this domain may help stabilize compromised ribosomes that accumulate when Der is defective. PMID: 23772068
- This meta-analysis suggests that there was no association between the NAT1*10 allele and bladder cancer risk. PMID: 23569127
- Upregulation of NAT1 is associated with estrogen receptor alpha-positive breast cancer. PMID: 23183268
- Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma. PMID: 23160945
- individuals with NAT2 genotype have an elevated risk of colorectal cancer; however, no evidence was found for association between NAT1 and 2 rapid genotype and colorectal adenoma risk PMID: 22905173
- NAT1 is a possible prognostic biomarker for male breast cancer. PMID: 22333393
- meta-analysis wasn't able to detect a significant association between polymorphisms in NAT1 and predisposition to colorectal carcinoma PMID: 22327651
- Data suggest that the 5'-UTRs of arylamine N-acetyltransferase 1 (NAT1) are differentially regulated. PMID: 21837760
- NAT1 14B-catalyzed acetylation phenotype is substrate-dependent; NAT1 14B exhibits higher N- and O-acetylation catalytic efficiency. PMID: 22010219
- the activities of the xenobiotic metabolizing phase II enzyme N-acetyltransferase 1 (NAT1) were higher in the late passages compared to the early passages PMID: 22686306
- NAT1 is transcribed from a major promoter, NATb, and an alternative promoter, NATa, resulting in messenger RNAs (mRNAs) with distinct 5'-untranslated regions (UTRs). PMID: 22114069
- NAT1 affects cell growth and morphology PMID: 21347396
- We observe a signature of balancing selection maintaining variation in the 3'-UTR of NAT1, suggesting that these variants may play a functional role. PMID: 21995608
- NAT1 *10 and *11 significantly increase NAT1 protein level/enzyme activity, enabling the classification of carriers into reference and rapid acetylators PMID: 21878835
- effects of polymorphisms within NAT1 coding region and 3'-UTR and associated haplotypes on catalytic activity and mRNA and protein levels; findings provide support for reported associations of 1088T>A and 1095C>A polymorphisms with birth defects PMID: 21290563
- There is a lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland. PMID: 20931357
- Only NAT1 showed a significant lower DNA methylation rate in the control group than in the tamoxifen-resistant breast cancer group, and no significant difference in methylation was found in COMT, CYP1A1, CYP2D6, and SULT1A1 genes. PMID: 20628863
- NAT1 and NAT2 gene combinations may influence the risk of developing head and neck cancer. PMID: 19898993
- There was no evidence of an increased risk associated with preference for well-done meat, intake of well-done meat, and NAT1 or NAT2 genotypes (jointly or separately). PMID: 20570911
- HSF1 is an important transcription factor for induction of NAT1 in human cells and is required for androgen activation of the NAT1 promoter. PMID: 20176657
- results suggest that the relationship between non-Hodgkin lymphoma and smoking status may be modified by common genetic variation in NAT1. PMID: 19809881
- the results of this study demonstrate that NAT1 activity may be important in breast cancer growth and metastasis. PMID: 20100460
- Slow metabolic phenotype of NAT1 combined with slow or intermediate NAT2 phenotype increases risk for occupational dermatitis PMID: 19834256
- NAT1 genotype acts as a modifier of diisothionate exposure-associated asthma risk PMID: 11927838
- paclitaxel is an uncompetitive inhibitor to arylamine N-acetyltransferase (NAT) enzyme PMID: 11955676
- paclitaxel affected human leukemia HL-60 cells arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adduct formation. PMID: 11955677
- NAT1 polymorphisms may be correlated with an increased risk of larynx cancer PMID: 12037388
- susceptibility gene for multifactorial adverse effects and xenobiotic-related diseases (review) PMID: 12052143
- NAT1 polymorphism (NAT1*10) indicates increased susceptibility to prostate cancer PMID: 12355549
- NAT1 * 10 has increased risk of sporadic colorectal adenocarcinoma and significantly related to the later stage tumors, is not significantly related to the tumor location PMID: 12485520
- Single nucleotide polymorphisms of NAT1 and NAT2, and acetylation haplotype were not associated with increased risk for Parkinson disease PMID: 12682333
- It is unlikely that the NAT1*10 or NAT2 rapid/intermediate genotypes are related to stomach cancer risk. PMID: 12692115
- Oxidative stress and cellular redox status may regulate NAT1 activity and have important consequences with regard to drug biotransformation and cancer risk. PMID: 12832400
顯示更多
收起更多
-
亞細胞定位:Cytoplasm.
-
蛋白家族:Arylamine N-acetyltransferase family
-
數(shù)據(jù)庫鏈接:
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-